External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ISHVLD 2021
Roche and Genentech at

ISHVLD 2021

June 18 - June 20
Virtual
ghs2020taipei.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:10 PM
Duration 10mins Virtual
Efficacy and safety of atezolizumab▼ + bevacizumab vs sorafenib in Taiwanese patients with unresectable HCC in the Phase III IMbrave150 study
Feng YH, Yen CJ, Yang TS, Chao Y, Su CY, Chen WJ, Hsiang HL, Cheng AL, Shao YY
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:10 PM
Duration 10mins Virtual
IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab▼ + bevacizumab vs sorafenib in patients with unresectable hepatocellular carcinoma
Cheng AL, Zhu AX, Ikeda M, Kim T-Y, Feng YH, Yen CJ, Yang TS, Chao Y, Li L, Wang Y, Ma N, Qin S
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.